Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of MRG002 in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma after at least one prior systemic chemotherapy regimen
CTR20210236Phase 2Completed
- Sponsor
- Hangzhou Miracogen
- Start
- Apr 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MRG002, sponsored by Hangzhou Miracogen. Started Apr 2021; status: completed.
02
Drugs
MRG002
Beyond the preview
Go deeper on CTR20210236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210236.